The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments In Vivo
Vaccinia virus (VACV) is a notorious virus for a number of scientific reasons; however, most of its notoriety comes from the fact that it was used as a vaccine against smallpox, being ultimately responsible for the eradication of that disease. Nonetheless, many different vaccinia virus strains have...
Saved in:
Published in | Journal of virology Vol. 93; no. 6 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Microbiology
15.03.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Vaccinia virus (VACV) is a notorious virus for a number of scientific reasons; however, most of its notoriety comes from the fact that it was used as a vaccine against smallpox, being ultimately responsible for the eradication of that disease. Nonetheless, many different vaccinia virus strains have been obtained over the years; some are suitable to be used as vaccines, whereas others are virulent and unsuitable for this purpose. Interestingly, different vaccinia virus strains elicit different immune responses
, and this is a direct result of the genomic differences among strains. In order to evaluate the net result of virus-encoded immune evasion strategies of vaccinia viruses, we compared antiviral immune responses in mice intranasally infected by the highly attenuated and nonreplicative MVA strain, the attenuated and replicative Lister strain, or the virulent WR strain. Overall, cell responses elicited upon WR infections are downmodulated compared to those elicited by MVA and Lister infections, especially in determined cell compartments such as macrophages/monocytes and CD4
T cells. CD4
T cells are not only diminished in WR-infected mice but also less activated, as evaluated by the expression of costimulatory molecules such as CD25, CD212, and CD28 and by the production of cytokines, including tumor necrosis factor alpha (TNF-α), gamma interferon (IFN-γ), interleukin-4 (IL-4), and IL-10. On the other hand, MVA infections are able to induce strong T-cell responses in mice, whereas Lister infections consistently induced responses that were intermediary between those induced by WR and MVA. Together, our results support a model in which the virulence of a VACV strain is proportional to its potential to downmodulate the host's immune responses.
Vaccinia virus was used as vaccine against smallpox and was instrumental in the successful eradication of that disease. Although smallpox vaccination is no longer in place in the overall population, the use of vaccinia virus in the development of viral vector-based vaccines has become popular. Nonetheless, different vaccinia virus strains are known and induce different immune responses. To look into this, we compared immune responses triggered by mouse infections with the nonreplicative MVA strain, the attenuated Lister strain, or the virulent WR strain. We observed that the WR strain was capable of downmodulating mouse cell responses, whereas the highly attenuated MVA strain induced high levels of cell-mediated immunity. Infections by the intermediately attenuated Lister strain induced cell responses that were intermediary between those induced by WR and MVA. We propose that the virulence of a vaccinia virus strain is directly proportional to its ability to downmodulate specific compartments of antiviral cell responses. |
---|---|
AbstractList | Vaccinia virus was used as vaccine against smallpox and was instrumental in the successful eradication of that disease. Although smallpox vaccination is no longer in place in the overall population, the use of vaccinia virus in the development of viral vector-based vaccines has become popular. Nonetheless, different vaccinia virus strains are known and induce different immune responses. To look into this, we compared immune responses triggered by mouse infections with the nonreplicative MVA strain, the attenuated Lister strain, or the virulent WR strain. We observed that the WR strain was capable of downmodulating mouse cell responses, whereas the highly attenuated MVA strain induced high levels of cell-mediated immunity. Infections by the intermediately attenuated Lister strain induced cell responses that were intermediary between those induced by WR and MVA. We propose that the virulence of a vaccinia virus strain is directly proportional to its ability to downmodulate specific compartments of antiviral cell responses.
Vaccinia virus (VACV) is a notorious virus for a number of scientific reasons; however, most of its notoriety comes from the fact that it was used as a vaccine against smallpox, being ultimately responsible for the eradication of that disease. Nonetheless, many different vaccinia virus strains have been obtained over the years; some are suitable to be used as vaccines, whereas others are virulent and unsuitable for this purpose. Interestingly, different vaccinia virus strains elicit different immune responses
in vivo
, and this is a direct result of the genomic differences among strains. In order to evaluate the net result of virus-encoded immune evasion strategies of vaccinia viruses, we compared antiviral immune responses in mice intranasally infected by the highly attenuated and nonreplicative MVA strain, the attenuated and replicative Lister strain, or the virulent WR strain. Overall, cell responses elicited upon WR infections are downmodulated compared to those elicited by MVA and Lister infections, especially in determined cell compartments such as macrophages/monocytes and CD4
+
T cells. CD4
+
T cells are not only diminished in WR-infected mice but also less activated, as evaluated by the expression of costimulatory molecules such as CD25, CD212, and CD28 and by the production of cytokines, including tumor necrosis factor alpha (TNF-α), gamma interferon (IFN-γ), interleukin-4 (IL-4), and IL-10. On the other hand, MVA infections are able to induce strong T-cell responses in mice, whereas Lister infections consistently induced responses that were intermediary between those induced by WR and MVA. Together, our results support a model in which the virulence of a VACV strain is proportional to its potential to downmodulate the host’s immune responses.
IMPORTANCE
Vaccinia virus was used as vaccine against smallpox and was instrumental in the successful eradication of that disease. Although smallpox vaccination is no longer in place in the overall population, the use of vaccinia virus in the development of viral vector-based vaccines has become popular. Nonetheless, different vaccinia virus strains are known and induce different immune responses. To look into this, we compared immune responses triggered by mouse infections with the nonreplicative MVA strain, the attenuated Lister strain, or the virulent WR strain. We observed that the WR strain was capable of downmodulating mouse cell responses, whereas the highly attenuated MVA strain induced high levels of cell-mediated immunity. Infections by the intermediately attenuated Lister strain induced cell responses that were intermediary between those induced by WR and MVA. We propose that the virulence of a vaccinia virus strain is directly proportional to its ability to downmodulate specific compartments of antiviral cell responses. Vaccinia virus (VACV) is a notorious virus for a number of scientific reasons; however, most of its notoriety comes from the fact that it was used as a vaccine against smallpox, being ultimately responsible for the eradication of that disease. Nonetheless, many different vaccinia virus strains have been obtained over the years; some are suitable to be used as vaccines, whereas others are virulent and unsuitable for this purpose. Interestingly, different vaccinia virus strains elicit different immune responses , and this is a direct result of the genomic differences among strains. In order to evaluate the net result of virus-encoded immune evasion strategies of vaccinia viruses, we compared antiviral immune responses in mice intranasally infected by the highly attenuated and nonreplicative MVA strain, the attenuated and replicative Lister strain, or the virulent WR strain. Overall, cell responses elicited upon WR infections are downmodulated compared to those elicited by MVA and Lister infections, especially in determined cell compartments such as macrophages/monocytes and CD4 T cells. CD4 T cells are not only diminished in WR-infected mice but also less activated, as evaluated by the expression of costimulatory molecules such as CD25, CD212, and CD28 and by the production of cytokines, including tumor necrosis factor alpha (TNF-α), gamma interferon (IFN-γ), interleukin-4 (IL-4), and IL-10. On the other hand, MVA infections are able to induce strong T-cell responses in mice, whereas Lister infections consistently induced responses that were intermediary between those induced by WR and MVA. Together, our results support a model in which the virulence of a VACV strain is proportional to its potential to downmodulate the host's immune responses. Vaccinia virus was used as vaccine against smallpox and was instrumental in the successful eradication of that disease. Although smallpox vaccination is no longer in place in the overall population, the use of vaccinia virus in the development of viral vector-based vaccines has become popular. Nonetheless, different vaccinia virus strains are known and induce different immune responses. To look into this, we compared immune responses triggered by mouse infections with the nonreplicative MVA strain, the attenuated Lister strain, or the virulent WR strain. We observed that the WR strain was capable of downmodulating mouse cell responses, whereas the highly attenuated MVA strain induced high levels of cell-mediated immunity. Infections by the intermediately attenuated Lister strain induced cell responses that were intermediary between those induced by WR and MVA. We propose that the virulence of a vaccinia virus strain is directly proportional to its ability to downmodulate specific compartments of antiviral cell responses. Vaccinia virus was used as vaccine against smallpox and was instrumental in the successful eradication of that disease. Although smallpox vaccination is no longer in place in the overall population, the use of vaccinia virus in the development of viral vector-based vaccines has become popular. Nonetheless, different vaccinia virus strains are known and induce different immune responses. To look into this, we compared immune responses triggered by mouse infections with the nonreplicative MVA strain, the attenuated Lister strain, or the virulent WR strain. We observed that the WR strain was capable of downmodulating mouse cell responses, whereas the highly attenuated MVA strain induced high levels of cell-mediated immunity. Infections by the intermediately attenuated Lister strain induced cell responses that were intermediary between those induced by WR and MVA. We propose that the virulence of a vaccinia virus strain is directly proportional to its ability to downmodulate specific compartments of antiviral cell responses. ABSTRACT Vaccinia virus (VACV) is a notorious virus for a number of scientific reasons; however, most of its notoriety comes from the fact that it was used as a vaccine against smallpox, being ultimately responsible for the eradication of that disease. Nonetheless, many different vaccinia virus strains have been obtained over the years; some are suitable to be used as vaccines, whereas others are virulent and unsuitable for this purpose. Interestingly, different vaccinia virus strains elicit different immune responses in vivo , and this is a direct result of the genomic differences among strains. In order to evaluate the net result of virus-encoded immune evasion strategies of vaccinia viruses, we compared antiviral immune responses in mice intranasally infected by the highly attenuated and nonreplicative MVA strain, the attenuated and replicative Lister strain, or the virulent WR strain. Overall, cell responses elicited upon WR infections are downmodulated compared to those elicited by MVA and Lister infections, especially in determined cell compartments such as macrophages/monocytes and CD4 + T cells. CD4 + T cells are not only diminished in WR-infected mice but also less activated, as evaluated by the expression of costimulatory molecules such as CD25, CD212, and CD28 and by the production of cytokines, including tumor necrosis factor alpha (TNF-α), gamma interferon (IFN-γ), interleukin-4 (IL-4), and IL-10. On the other hand, MVA infections are able to induce strong T-cell responses in mice, whereas Lister infections consistently induced responses that were intermediary between those induced by WR and MVA. Together, our results support a model in which the virulence of a VACV strain is proportional to its potential to downmodulate the host’s immune responses. IMPORTANCE Vaccinia virus was used as vaccine against smallpox and was instrumental in the successful eradication of that disease. Although smallpox vaccination is no longer in place in the overall population, the use of vaccinia virus in the development of viral vector-based vaccines has become popular. Nonetheless, different vaccinia virus strains are known and induce different immune responses. To look into this, we compared immune responses triggered by mouse infections with the nonreplicative MVA strain, the attenuated Lister strain, or the virulent WR strain. We observed that the WR strain was capable of downmodulating mouse cell responses, whereas the highly attenuated MVA strain induced high levels of cell-mediated immunity. Infections by the intermediately attenuated Lister strain induced cell responses that were intermediary between those induced by WR and MVA. We propose that the virulence of a vaccinia virus strain is directly proportional to its ability to downmodulate specific compartments of antiviral cell responses. |
Author | Faria, Ana Maria C da Fonseca, Flávio G Oliveira, Rafael P Rocha, Raíssa P de Freitas, Lorena F D Barbosa-Stancioli, Edel F Miranda, Mariana C G |
Author_xml | – sequence: 1 givenname: Lorena F D surname: de Freitas fullname: de Freitas, Lorena F D organization: Laboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil – sequence: 2 givenname: Rafael P surname: Oliveira fullname: Oliveira, Rafael P organization: Instituto Federal do Paraná, Palmas, PR, Brazil – sequence: 3 givenname: Mariana C G surname: Miranda fullname: Miranda, Mariana C G organization: Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil – sequence: 4 givenname: Raíssa P surname: Rocha fullname: Rocha, Raíssa P organization: Laboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil – sequence: 5 givenname: Edel F surname: Barbosa-Stancioli fullname: Barbosa-Stancioli, Edel F organization: Laboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil – sequence: 6 givenname: Ana Maria C surname: Faria fullname: Faria, Ana Maria C organization: Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil – sequence: 7 givenname: Flávio G surname: da Fonseca fullname: da Fonseca, Flávio G email: fdafonseca@icb.ufmg.br organization: Laboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil fdafonseca@icb.ufmg.br |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30567985$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkU1r3DAQhkVJaTZpbz0XHXuoU8m2tPKlEDb92JDSQpalNyHLo0ZFlhxJTtk_k98a5ZPkNDDz8r4z8xygPR88IPSekiNKa_H5dLs-IjXtaEXFK7SgpBMVY7TdQwtC6rpijfizjw5S-kcIbVvevkH7DWF82Qm2QNebC8BbG2cHXgMOBp9YYyCCz3irtLbeqrt5wuc5KusTXqeiiaCz2-HfMUwhZhu8cjgHXNxsxMe9dTbv8Cbgk_Dfj2GYncqAzyfQ1liNV-Bc9RMGW7oDXo_j7AGvwjipmMcSXUJ8Sb0Kb9Fro1yCdw_1EG2-fd2sflRnv76vV8dnlW5EmyvVc357kiBs4D1Xvebdki1pw0zDlO6XRNS6V9CbvulIR4Uh0NWcGUP0YKA5RF_ubae5H2HQZYWonJyiHVXcyaCsfDnx9kL-DVeSt-WnnBaDjw8GMVzOkLIcbdLlSuUhzEnWlHVNgURYkX66l-oYUopgnmIokbdEZSEq74hKKor8w_PVnsSPCJsb7e-hzg |
CitedBy_id | crossref_primary_10_3390_microorganisms9010042 crossref_primary_10_1002_cti2_1392 crossref_primary_10_1186_s12985_021_01595_z crossref_primary_10_3389_fimmu_2019_01780 crossref_primary_10_1016_j_celrep_2024_113882 crossref_primary_10_1016_j_mehy_2020_109556 crossref_primary_10_3389_fimmu_2022_867918 crossref_primary_10_3390_biomedicines10092289 |
Cites_doi | 10.1016/S1473-3099(15)00362-X 10.4137/CMO.S7654 10.1128/JVI.74.2.923-933.2000 10.1128/jvi.67.12.7623-7628.1993 10.3201/eid0706.010602 10.1016/j.antiviral.2009.06.006 10.1128/JVI.05779-11 10.1146/annurev.iy.11.040193.001203 10.1128/JVI.00756-10 10.1016/j.vaccine.2013.06.073 10.1038/nm1128 10.1128/JVI.74.16.7651-7655.2000 10.1016/j.vaccine.2011.08.098 10.1016/j.vaccine.2008.09.016 10.1038/sj.cgt.7700937 10.1007/s00705-003-0006-z 10.4049/jimmunol.172.10.6265 10.1016/j.vaccine.2006.02.012 10.1186/1471-2334-1-9 10.1189/jlb.4MA0815-376RR 10.1128/JVI.01997-08 10.1038/ni1179 10.1086/592507 10.1371/journal.pone.0007428 10.1006/viro.1998.9123 10.1038/icb.2014.10 10.1055/s-0028-1108143 10.1099/0022-1317-79-5-1159 10.1128/JVI.01042-17 10.1128/JVI.00945-06 10.1099/0022-1317-72-5-1031 10.1089/10430340460745757 10.1099/0022-1317-1-3-399 10.1371/journal.pone.0149364 10.1177/095632020101200105 10.1128/jvi.70.12.8301-8309.1996 10.1007/s00436-008-1150-x 10.1002/9780471729259.mca04is17 10.1099/vir.0.055921-0 10.1371/journal.pone.0114374 10.1371/journal.pone.0003043 10.1128/JVI.01894-15 10.1038/cmi.2014.128 10.1155/2012/974067 10.1128/JVI.02797-14 10.1073/pnas.89.22.10847 10.1073/pnas.0406381102 10.1038/s41598-017-08719-y 10.1111/j.0818-9641.2004.01243.x 10.1128/JVI.79.16.10397-10407.2005 10.1099/vir.0.19285-0 |
ContentType | Journal Article |
Copyright | Copyright © 2019 American Society for Microbiology. Copyright © 2019 American Society for Microbiology. 2019 American Society for Microbiology |
Copyright_xml | – notice: Copyright © 2019 American Society for Microbiology. – notice: Copyright © 2019 American Society for Microbiology. 2019 American Society for Microbiology |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1128/JVI.02191-18 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
DocumentTitleAlternate | Modulation of Host Immunity by Vaccinia Virus Strains |
EISSN | 1098-5514 |
Editor | Sandri-Goldin, Rozanne M. |
Editor_xml | – sequence: 1 givenname: Rozanne M. surname: Sandri-Goldin fullname: Sandri-Goldin, Rozanne M. |
ExternalDocumentID | 10_1128_JVI_02191_18 30567985 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: ; grantid: NA |
GroupedDBID | --- -~X 0R~ 18M 29L 2WC 39C 4.4 53G 5GY 5RE 5VS 85S ABPPZ ACGFO ACNCT ADBBV AENEX AGVNZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW CGR CS3 CUY CVF DIK E3Z EBS ECM EIF EJD F5P FRP GX1 H13 HYE HZ~ IH2 KQ8 N9A NPM O9- OK1 P2P RHF RHI RNS RPM RSF TR2 UCJ UPT W2D W8F WH7 WOQ YQT ~02 ~KM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c384t-ab660567805d6b6abc69757135f35acb7082cbaebfb390918f0e9265ff0cdfe3 |
IEDL.DBID | RPM |
ISSN | 0022-538X |
IngestDate | Tue Sep 17 21:15:39 EDT 2024 Fri Oct 25 07:51:43 EDT 2024 Thu Sep 12 17:16:58 EDT 2024 Sat Sep 28 08:29:17 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | Western Reserve strain MVA Lister strain vaccinia virus mouse model modulation of the host immune response |
Language | English |
License | Copyright © 2019 American Society for Microbiology. All Rights Reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c384t-ab660567805d6b6abc69757135f35acb7082cbaebfb390918f0e9265ff0cdfe3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Citation de Freitas LFD, Oliveira RP, Miranda MCG, Rocha RP, Barbosa-Stancioli EF, Faria AMC, da Fonseca FG. 2019. The virulence of different vaccinia virus strains is directly proportional to their ability to downmodulate specific cell-mediated immune compartments in vivo. J Virol 93:e02191-18. https://doi.org/10.1128/JVI.02191-18. |
OpenAccessLink | https://jvi.asm.org/content/jvi/93/6/e02191-18.full.pdf |
PMID | 30567985 |
PQID | 2159321905 |
PQPubID | 23479 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6401461 proquest_miscellaneous_2159321905 crossref_primary_10_1128_JVI_02191_18 pubmed_primary_30567985 |
PublicationCentury | 2000 |
PublicationDate | 2019-03-15 |
PublicationDateYYYYMMDD | 2019-03-15 |
PublicationDate_xml | – month: 03 year: 2019 text: 2019-03-15 day: 15 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
PublicationTitle | Journal of virology |
PublicationTitleAlternate | J Virol |
PublicationYear | 2019 |
Publisher | American Society for Microbiology |
Publisher_xml | – name: American Society for Microbiology |
References | e_1_3_2_26_2 e_1_3_2_28_2 Mayr A (e_1_3_2_5_2) 1978; 167 e_1_3_2_41_2 e_1_3_2_20_2 e_1_3_2_43_2 e_1_3_2_22_2 e_1_3_2_45_2 e_1_3_2_24_2 e_1_3_2_47_2 e_1_3_2_9_2 e_1_3_2_16_2 e_1_3_2_37_2 e_1_3_2_7_2 e_1_3_2_18_2 e_1_3_2_39_2 Nicol MP (e_1_3_2_19_2) 2010; 12 e_1_3_2_54_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_52_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_3_2 e_1_3_2_14_2 e_1_3_2_35_2 e_1_3_2_50_2 e_1_3_2_27_2 e_1_3_2_48_2 e_1_3_2_29_2 e_1_3_2_40_2 e_1_3_2_21_2 e_1_3_2_42_2 e_1_3_2_23_2 e_1_3_2_44_2 e_1_3_2_25_2 e_1_3_2_46_2 e_1_3_2_15_2 e_1_3_2_38_2 e_1_3_2_8_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_30_2 e_1_3_2_53_2 e_1_3_2_32_2 e_1_3_2_51_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_4_2 e_1_3_2_13_2 e_1_3_2_36_2 Jelinkova A (e_1_3_2_49_2) 1973; 17 e_1_3_2_55_2 e_1_3_2_2_2 |
References_xml | – ident: e_1_3_2_20_2 doi: 10.1016/S1473-3099(15)00362-X – ident: e_1_3_2_21_2 doi: 10.4137/CMO.S7654 – ident: e_1_3_2_40_2 doi: 10.1128/JVI.74.2.923-933.2000 – ident: e_1_3_2_54_2 doi: 10.1128/jvi.67.12.7623-7628.1993 – ident: e_1_3_2_11_2 doi: 10.3201/eid0706.010602 – ident: e_1_3_2_3_2 doi: 10.1016/j.antiviral.2009.06.006 – ident: e_1_3_2_12_2 doi: 10.1128/JVI.05779-11 – ident: e_1_3_2_34_2 doi: 10.1146/annurev.iy.11.040193.001203 – ident: e_1_3_2_36_2 doi: 10.1128/JVI.00756-10 – ident: e_1_3_2_13_2 doi: 10.1016/j.vaccine.2013.06.073 – ident: e_1_3_2_18_2 doi: 10.1038/nm1128 – ident: e_1_3_2_42_2 doi: 10.1128/JVI.74.16.7651-7655.2000 – ident: e_1_3_2_14_2 doi: 10.1016/j.vaccine.2011.08.098 – ident: e_1_3_2_15_2 doi: 10.1016/j.vaccine.2008.09.016 – ident: e_1_3_2_23_2 doi: 10.1038/sj.cgt.7700937 – ident: e_1_3_2_28_2 doi: 10.1007/s00705-003-0006-z – ident: e_1_3_2_25_2 doi: 10.4049/jimmunol.172.10.6265 – ident: e_1_3_2_41_2 doi: 10.1016/j.vaccine.2006.02.012 – ident: e_1_3_2_46_2 doi: 10.1186/1471-2334-1-9 – ident: e_1_3_2_51_2 doi: 10.1189/jlb.4MA0815-376RR – ident: e_1_3_2_45_2 doi: 10.1128/JVI.01997-08 – ident: e_1_3_2_50_2 doi: 10.1038/ni1179 – ident: e_1_3_2_16_2 doi: 10.1086/592507 – ident: e_1_3_2_30_2 doi: 10.1371/journal.pone.0007428 – ident: e_1_3_2_7_2 doi: 10.1006/viro.1998.9123 – ident: e_1_3_2_52_2 doi: 10.1038/icb.2014.10 – ident: e_1_3_2_6_2 doi: 10.1055/s-0028-1108143 – ident: e_1_3_2_9_2 doi: 10.1099/0022-1317-79-5-1159 – ident: e_1_3_2_26_2 doi: 10.1128/JVI.01042-17 – ident: e_1_3_2_2_2 doi: 10.1128/JVI.00945-06 – ident: e_1_3_2_8_2 doi: 10.1099/0022-1317-72-5-1031 – ident: e_1_3_2_22_2 doi: 10.1089/10430340460745757 – ident: e_1_3_2_39_2 doi: 10.1099/0022-1317-1-3-399 – ident: e_1_3_2_44_2 doi: 10.1371/journal.pone.0149364 – ident: e_1_3_2_38_2 doi: 10.1177/095632020101200105 – ident: e_1_3_2_33_2 doi: 10.1128/jvi.70.12.8301-8309.1996 – volume: 12 start-page: 124 year: 2010 ident: e_1_3_2_19_2 article-title: MVA-85a, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults publication-title: Curr Opin Mol Ther contributor: fullname: Nicol MP – ident: e_1_3_2_47_2 doi: 10.1007/s00436-008-1150-x – ident: e_1_3_2_55_2 doi: 10.1002/9780471729259.mca04is17 – ident: e_1_3_2_24_2 doi: 10.1099/vir.0.055921-0 – ident: e_1_3_2_43_2 doi: 10.1371/journal.pone.0114374 – ident: e_1_3_2_29_2 doi: 10.1371/journal.pone.0003043 – ident: e_1_3_2_53_2 doi: 10.1128/JVI.01894-15 – ident: e_1_3_2_31_2 doi: 10.1038/cmi.2014.128 – ident: e_1_3_2_27_2 doi: 10.1155/2012/974067 – ident: e_1_3_2_4_2 doi: 10.1128/JVI.02797-14 – ident: e_1_3_2_10_2 doi: 10.1073/pnas.89.22.10847 – ident: e_1_3_2_17_2 doi: 10.1073/pnas.0406381102 – volume: 17 start-page: 124 year: 1973 ident: e_1_3_2_49_2 article-title: Electron microscope study of the course of poxvirus officinale infection in cultures of alveolar macrophages publication-title: Acta Virol contributor: fullname: Jelinkova A – volume: 167 start-page: 375 year: 1978 ident: e_1_3_2_5_2 article-title: The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism publication-title: Zentralbl Bakteriol B contributor: fullname: Mayr A – ident: e_1_3_2_32_2 doi: 10.1038/s41598-017-08719-y – ident: e_1_3_2_35_2 doi: 10.1111/j.0818-9641.2004.01243.x – ident: e_1_3_2_48_2 doi: 10.1128/JVI.79.16.10397-10407.2005 – ident: e_1_3_2_37_2 doi: 10.1099/vir.0.19285-0 |
SSID | ssj0014464 |
Score | 2.3803518 |
Snippet | Vaccinia virus (VACV) is a notorious virus for a number of scientific reasons; however, most of its notoriety comes from the fact that it was used as a vaccine... Vaccinia virus was used as vaccine against smallpox and was instrumental in the successful eradication of that disease. Although smallpox vaccination is no... |
SourceID | pubmedcentral proquest crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
SubjectTerms | Animals CD4-Positive T-Lymphocytes - immunology CD4-Positive T-Lymphocytes - virology Chickens - immunology Chickens - virology Chlorocebus aethiops - immunology Chlorocebus aethiops - virology Cytokines - immunology Genetic Vectors - immunology Immunity, Cellular - immunology Mice Mice, Inbred BALB C Pathogenesis and Immunity Smallpox - immunology Vaccination - methods Vaccinia - immunology Vaccinia - virology Vaccinia virus - immunology Viral Vaccines - immunology Virulence - immunology |
Title | The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments In Vivo |
URI | https://www.ncbi.nlm.nih.gov/pubmed/30567985 https://search.proquest.com/docview/2159321905 https://pubmed.ncbi.nlm.nih.gov/PMC6401461 |
Volume | 93 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1dT9swFL0CpEm8TGMbW8eHLtJ4TNt82EkeUQFREBMSXdW3yHZsLVKboDZF6p_ht3LtJAjGG89O7MjHH-fGx_cA_NapTAOec08nofQid88nDI0X5YrwjwNF71m1xR9-9Te6nrHZFrDuLowT7StZ9Mv5ol8W_5y28mGhBp1ObHB3O-KRTXniD7ZhmwZoF6K3RwcU30RdinCazbNO7R4kg-vpuE97Wup7vvXps-w5Tq2L8ust6R3P_F8u-Wr_ufwCn1viiGfNB-7Bli6_wqfGSnLzDZ4Ib5wWy7W7RISVwfPW-qTGqVCqKAvhyld472whVjheYbPgzTd4Z80Sls1_QawrnNjzAzxzytkNTio8p2h9UeXW7EujM603hcKRns-9W-f2oXMc27smGt0Ss3TqdWqkpFYfq-8wubyYjK681nvBU2ES1Z6QnNvuSYYs55ILqXgaM-vnZ0ImlIyJOigptDQyTIlzJGaoCXRmzFDlRof7sFNWpf4JGAiimLlNXScNsTUjYhaZkMI0f6glVdqD0673s4cmw0bmIpMgyQiwzAGW-UkPTjpoMpoC9lxDlLparzJiLcRCidmwHvxooHqpqcO4B_EbEF8esOm135bQqHNptttR9uvDbx7ALtGr1CrWfHYIO_VyrY-IwtTymMj7-ObYDdxnoBz0SQ |
link.rule.ids | 230,315,730,783,787,888,27936,27937,53804,53806 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswEB2kKYr20j2tu06B9ihZ-3IMnAZ2GgcBohq-CSRFokJtybDlBO7H9Fs7pKQgSU_teSRS0gzJR_HNPIDPMuWpFxWRJROfW4HJ8_F9ZQWFIP_HnqD7NNviLBp_D07m4XwPwj4XxpD2BS_tarG0q_KH4VaulmLY88SG59NRFOiSJ-7wHtyn8eoE_Sa9OzygHU7QFwkn-7znu3vJ8GQ2sWlVS13L1Up9Gj_HqdZRvrko_YU07xImb6xAx09g1j97Szz5aW8bbotfd8o6_vPLPYXHHSbFw9b8DPZk9RwetCqVuxfwm0IJZ-V6a_KTsFZ41KmqNDhjQpRVyYx9gxdGcWKDkw22c-lih-dah2Hd_nLEpsZMH03goSHl7jCr8ai-qpZ1oXXEJF6spGEJ4kguFtbUCInIAic6jUWimb3WhhhPnVTU62X9ErLjr9lobHWyDpbwk6CxGI8i_d0TJywiHjEuojQOtVSg8kMmeEyoRHAmueJ-SnAmUY6keAqVckShpH8A-1VdydeAHiP0WuiqeFwREFQsDgPl0w7QdSSnRgfwpXdrvmqLd-Rm0-MlOUVCbiIhd5MBfOp9ntPo0kcmrJL1dpMTICKAS6ApHMCrNgauW-qDZwDxrei4vkBX7r5tIZ-bCt6dj9_8950f4eE4m57mp5Ozb2_hEaG4VBPj3PAd7DfrrXxPSKnhH8y4-AMCYhVL |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgEYgL70d5DhIc806c5LhqqbYLu6q0paq4RLZji4jWqdoUVH4Mv5Wxk6y6y23PfiWZsf1N_Hk-Qj7KnOchLakjs4g7sb3nE0XKiUuB9k9Dge0M2-KcnnyLTxfJ4kDqy5L2Ba9cvVy5uvphuZXrlfB6npg3PRvS2KQ8Cbx1qbzb5A7OWZ_2gXp3gIBRTtwnCsfyRc95DzPvdD5xcWfLAycwan0GQ6e50VI-3Jj-Q5vXSZMHu9D4IfneP39LPvnp7hruij_XUjve6AUfkQcdNoXjtspjckvqJ-Ruq1a5f0r-okvBvNrs7D0lqBWMOnWVBuZMiEpXzJZv4cIqT2xhsoV2TV3uYWr0GDbtr0doapiZIwo4tuTcPcxqGNW_9aoujZ6YhIu1tGxBGMrl0jmzgiKyhIm5ziLBrmIbS5DHQTSO-qt-Rmbjz7PhidPJOzgiyuLGYZxS8-0zPykpp4wLmqeJkQxUUcIETxGdCM4kVzzKEdZkypfoV4lSviiVjJ6TI11r-ZJAyBDFliY7HlcICBVLk1hFGAkGvuTY6YB86k1brNskHoUNfsKsQG8orDcUQTYgH3q7FzjLzNEJ07LebQsERgh0ETwlA_Ki9YPLnnoHGpD0iodcVjAZvK-WoN1tJu_Ozq9u3PI9uTcdjYuvk_Mvr8l9BHO54ccFyRty1Gx28i0Cpoa_s1PjH57WF8s |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Virulence+of+Different+Vaccinia+Virus+Strains+Is+Directly+Proportional+to+Their+Ability+To+Downmodulate+Specific+Cell-Mediated+Immune+Compartments+In+Vivo&rft.jtitle=Journal+of+virology&rft.au=de+Freitas%2C+Lorena+F+D&rft.au=Oliveira%2C+Rafael+P&rft.au=Miranda%2C+Mariana+C+G&rft.au=Rocha%2C+Ra%C3%ADssa+P&rft.date=2019-03-15&rft.eissn=1098-5514&rft.volume=93&rft.issue=6&rft_id=info:doi/10.1128%2FJVI.02191-18&rft_id=info%3Apmid%2F30567985&rft.externalDocID=30567985 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-538X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-538X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-538X&client=summon |